Our diversified portfolio spans oncology, neurology, immunology, and rare diseases, leveraging proprietary platforms in mRNA, CRISPR, and monoclonal antibodies to accelerate patient access.
| Candidate | Target / Modality | Indication | Phase | Status | Region |
|---|---|---|---|---|---|
| ZTH-1042 | PD-1 / LAG-3 Bi-specific | Advanced Solid Tumors | Phase III | Active | Global |
| ZTH-2098 | Tau Aggregation Inhibitor | Alzheimer's Disease | Phase II | Active | US / EU |
| ZTH-3011 | IL-23 Inhibitor (mAb) | Plaque Psoriasis | Approved | Launched | Global |
| ZTH-4077 | SGLT2 / GIP / GLP-1 Tri-agonist | Type 2 Diabetes & Obesity | Phase II | Active | US |
| ZTH-5023 | CRISPR-Cas9 Gene Edit | Sickle Cell Disease | Phase I | Active | US / EU |
| ZTH-6089 | NMDA Receptor Modulator | Major Depressive Disorder | Phase III | Active | Global |
| ZTH-0094 | mTOR Inhibitor | Rare Childhood Cancers | Preclinical | Discovery | US |
| ZTH-7712 | Anti-Pf41 Antibody | Severe Malaria | Phase II | Active | APAC / AFR |
| ZTH-8845 | Cardiac Sodium Channel Blocker | Ventricular Arrhythmia | Discontinued | Halted | US / EU |